Paola Viani

Prof. Paola Viani


Research Focus & Metrics

Academic Career Length

44Years (1983-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 January 2012 in The EMBO Journal
Verified
Journal Article
Open access
PDF file
FAFlavia Antonucci
Flavia Antonucci
ETElena Turola
Elena Turola
LRLoredana Riganti
Loredana Riganti
MCMatteo Caleo
Matteo Caleo
Martina GabrielliMartina Gabrielli
Martina Gabrielli
CFChiara Fenoglio
Chiara Fenoglio
Microvesicles (MVs) released into the brain microenvironment are emerging as a novel way of cell‐to‐cell communication. We have recently shown that microglia, the immune cells of the brain, shed MVs upon activation but their possible role in microglia‐to‐neuron communication has never been explored. To investigate whether MVs affect neurotransmission, we analysed spontaneous release of glutamate in neurons exposed to MVs and found a dose‐dependent increase in miniature excitatory postsynaptic current (mEPSC) frequency without changes in mEPSC amplitude. Paired‐pulse recording analysis of evoked neurotransmission showed that MVs mainly act at the presynaptic site, by increasing release probability. In line with the enhancement of excitatory transmission in vitro , injection of MVs into the rat visual cortex caused an acute increase in the amplitude of field potentials evoked by visual stimuli. Stimulation of synaptic activity occurred via enhanced sphingolipid metabolism. Indeed, MVs promoted ceramide and sphingosine production in neurons, while the increase of excitatory transmission induced by MVs was prevented by pharmacological or genetic inhibition of sphingosine synthesis. These data identify microglia‐derived MVs as a new mechanism by which microglia influence synaptic activity and highlight the involvement of neuronal sphingosine in this microglia‐to‐neuron signalling pathway.

1 September 1997 in Progress in Lipid Research
Verified
Journal Article
Closed access
Laura RiboniLaura Riboni
Laura Riboni
PVPaola Viani
Paola Viani
Roberto BassiRoberto Bassi
Roberto Bassi
APAlessandro Prinetti
Alessandro Prinetti
GTGuido Tettamanti
Guido Tettamanti

1 March 2003 in Biochimie
Verified
Journal Article
Closed access
GTG Tettamanti
G Tettamanti
Roberto BassiRoberto Bassi
Roberto Bassi
PVPaola Viani
Paola Viani
Laura RiboniLaura Riboni
Laura Riboni

1 January 1991 in Journal of Neurochemistry
Verified
Journal Article
Closed access
PDF file
PVPaola Viani
Paola Viani
GCGiovanna Cervato
Giovanna Cervato
AFAmelia Fiorilli
Amelia Fiorilli
BCBenvenuto Cestaro
Benvenuto Cestaro

Verified
Journal Article
Open access
PDF file
Paola GiussaniPaola Giussani
Paola Giussani
CTCristina Alessandra Tringali
Cristina Alessandra Tringali
Laura RiboniLaura Riboni
Laura Riboni
PVPaola Viani
Paola Viani
BVBruno Venerando
Bruno Venerando
Drug resistance elicited by cancer cells still constitutes a huge problem that frequently impairs the efficacy of both conventional and novel molecular therapies. Chemotherapy usually acts to induce apoptosis in cancer cells; therefore, the investigation of apoptosis control and of the mechanisms used by cancer cells to evade apoptosis could be translated in an improvement of therapies. Among many tools acquired by cancer cells to this end, the de-regulated synthesis and metabolism of sphingolipids have been well documented. Sphingolipids are known to play many structural and signalling roles in cells, as they are involved in the control of growth, survival, adhesion, and motility. In particular, in order to increase survival, cancer cells: (a) counteract the accumulation of ceramide that is endowed with pro-apoptotic potential and is induced by many drugs; (b) increase the synthesis of sphingosine-1-phosphate and glucosylceramide that are pro-survivals signals; (c) modify the synthesis and the metabolism of complex glycosphingolipids, particularly increasing the levels of modified species of gangliosides such as 9-O acetylated GD3 (αNeu5Ac(2-8)αNeu5Ac(2-3)βGal(1-4)βGlc(1-1)Cer) or N-glycolyl GM3 (αNeu5Ac (2-3)βGal(1-4)βGlc(1-1)Cer) and de-N-acetyl GM3 (NeuNH(2)βGal(1-4)βGlc(1-1)Cer) endowed with anti-apoptotic roles and of globoside Gb3 related to a higher expression of the multidrug resistance gene MDR1. In light of this evidence, the employment of chemical or genetic approaches specifically targeting sphingolipid dysregulations appears a promising tool for the improvement of current chemotherapy efficacy.

20 May 2002 in Glia
Verified
Journal Article
Closed access
PDF file
Laura RiboniLaura Riboni
Laura Riboni
RCRolando Campanella
Rolando Campanella
Roberto BassiRoberto Bassi
Roberto Bassi
RVRoberto Villani
Roberto Villani
SGSergio M. Gaini
Sergio M. Gaini
GTGuido Tettamanti
Guido Tettamanti